On Invalid Date, Avalo Therapeutics (NASDAQ: AVTX) reported Q3 2023 earnings per share (EPS) of -$26.40, up 132.35% year over year. Total Avalo Therapeutics earnings for the quarter were -$5.23 million. In the same quarter last year, Avalo Therapeutics's earnings per share (EPS) was $81.60.
As of Q1 2024, Avalo Therapeutics's earnings has grown year over year. Avalo Therapeutics's earnings in the past year totalled -$33.19 million.
What is AVTX's earnings date?
Avalo Therapeutics's earnings date is Invalid Date. Add AVTX to your watchlist to be reminded of AVTX's next earnings announcement.
What was AVTX's revenue last quarter?
On Invalid Date, Avalo Therapeutics (NASDAQ: AVTX) reported Q3 2023 revenue of $236.00 thousand up 98.42% year over year. In the same quarter last year, Avalo Therapeutics's revenue was $14.95 million.
What was AVTX's revenue growth in the past year?
As of Q1 2024, Avalo Therapeutics's revenue has grown -87.05% year over year. This is 252.66 percentage points lower than the US Biotechnology industry revenue growth rate of 165.61%. Avalo Therapeutics's revenue in the past year totalled $2.25 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.